Constellation Pharmaceuticals Lands $55,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=54c694e2-73bc-43f0-927e-6cfc05c328c0 - Date
12/10/2015 - Company Name
Constellation Pharmaceuticals - Mailing Address
215 First Street Cambridge, MA 02142 USA - Company Description
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. - Website
http://www.constellationpharma.com - Transaction Type
Venture Equity - Transaction Amount
$55,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
The Company plans to use the proceeds from the financing to advance its pipeline of direct tumor targeting and immuno-stimulatory epigenetic inhibitors, which includes its two wholly-owned, clinical-stage lead programs: a bromodomain and extra-terminal (BET) inhibitor as well as an EZH2 inhibitor, targeting difficult-to-treat cancers. - M&A Terms
- Venture Investor
Topspin Partners - Venture Investor
Third Rock Ventures - Venture Investor
The Column Group - Venture Investor
Venrock - Venture Investor
SR One - Venture Investor
Undisclosed
